NDAINTRAVENOUSSOLUTION
Approved
Jul 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
BORTEZOMIB (bortezomib) by Accord Biopharma is chymotrypsin-like activity of the 26s proteasome in mammalian cells. Approved for multiple myeloma, relapsed or refractory multiple myeloma, mantle cell lymphoma. First approved in 2022.
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Bortezomib is a small-molecule proteasome inhibitor that blocks the 26S proteasome's chymotrypsin-like activity, preventing degradation of ubiquitinated proteins and triggering cancer cell death. It is indicated for multiple myeloma (including relapsed/refractory disease) and mantle cell lymphoma. The drug represents a foundational mechanism in hematologic oncology with decades of clinical validation.
Peak
Product is in peak commercial phase with established market presence; teams are focused on market penetration and optimization rather than launch activities.
Mechanism of Action
chymotrypsin-like activity of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining…
Indications (3)
Worked on BORTEZOMIB at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.